Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
On Jan. 11, CMS released a proposed coverage decision that would cover the costs of monoclonal antibody treatments for Alzheimer's Disease patients only if they are enrolled in clinical trials.
AMCP joins other organizations in a letter of support for Dr. Robert Califf's nomination for FDA Commissioner.
On December 8, AMCP sent a letter of support to the Senate for Dr. Robert Califf's nomination to be FDA Commissioner.
AMCP joined other organizations to call on the business community to support the new federal requirement that those working for companies with more than 100 employees be vaccinated for COVID.
On Oct. 28, AMCP joined a pharmacy stakeholder coalition letter to HHS requesting authorizations for pharmacists, pharmacy technicians and interns to order and administer antiviral medications and flu tests.
On Nov. 2, AMCP joined a pharmacy stakeholder coalition letter to CMS requesting the agency use its PREP Act authority to establish payment mechanisms for Medicare and Medicaid to reimburse pharmacists for COVID-19 patient assessment services.
In October, AMCP joined other pharmacy organizations in supporting the Pharmacist's Fundamental Responsibilities and Rights released by APhA and the National Alliance of State Pharmacy Associations (NASPA). These principles focus on pharmacists' responsibilities and the workplace conditions necessary to fulfill those responsibilities.
AMCP submitted comments on the proposed FDA Prescription Drug User Fee Act Reauthorization commitment letter, supporting the agency's plans to increase resources for approval of cell and gene therapies and continued exploration of uses for real-world evidence in regulatory decision-making.
Pharmacy associations offer condolences to families of pharmacist and two others killed in Maryland.
On Sept. 14, AMCP joined a Medicaid stakeholder letter urging Congress to include language that requires 12-month continuous eligibility for children on Medicaid and the Children’s Health Insurance Program (CHIP) in the reconciliation bill.
Letter requests an immediate amendment to the PREP Act declaration on COVID-19, which would allow pharmacists to order and administer REGEN-COV and future authorized products for the treatment of COVID-19.
On July 28, AMCP provided comments on PQA's prospective strategic and broad-reaching goals.
